EFICACIA DE LOS BOLOS INTRAVENOSOS DE CORTICOIDES MÁS TRATAMIENTO CON CORTICOIDES ORALES EN COMPARACIÓN CON CORTICOIDES ORALES EN MONOTERAPIA PARA EL TRATAMIENTO DE LA COLITIS ULCEROSA MODERADA: ENSAYO CLÍNICO MULTICÉNTRICO Y ALEATORIZADO.

Dades bàsiques

Protocol:
CECUM
EURDRACT:
2016-001170-15
NCT:
Centre:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Any inici:
2019
Any de finalització:
2021
ENSAYO CLÍNICO NACIONAL

Documents

  • No hi ha documents

Participants

Grups d'Investigació

Finançadors - Promotors

GETECCU - GRUPO ESPAÑOL DE TRABAJO EN ENFERMEDAD DE CROHN Y COLITIS ULCEROSA

Resultats de l'Assaig Clínic


2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021

  • Open Access.

A long-term prospective study of the efficacy and safety of endoscopic septotomy using the LigaSure (R) system for the treatment of Zenker's diverticulum

Pons-Beltran, V; (...); Arguello, L

Article. 10.17235/reed.2019.5915/2018. 2019

  • Open Access.

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022

  • Open Access.

A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.

de Andrés-Nogales F; (...); Martínez-Olmos J

Article. 10.1007/s41669-020-00201-2. 2020

  • Open Access.

A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

Casado, MA; (...); Grp MULTIDEX-EMD

Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018

  • Open Access.

A new definition and refocus of pharmaceutical care: the Barbate Document

Morillo-Verdugo R; (...); Poveda-Andrés JL

Article. 10.7399/fh.11389. 2020

  • Open Access.

A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.

Cerrillo E; (...); Beltrán B

Article. 10.1093/ibd/izz053. 2019


A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial

Del Hoyo, Javier; (...); Aguas, Mariam

Article. 10.2196/11602. 2018

  • Open Access.

A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial

Aguas, Mariam; (...); Nos, Pilar

Article. 10.2196/resprot.9639. 2018

  • Open Access.

Acute cholecystitis after colonoscopy: A rare complication.

Ladrón Abia P; (...); Del Hoyo F

Article. 10.1016/j.rgmxen.2022.05.007. 2022


Acute myocardial infarction in a patient with a recent diagnosis of Crohn's disease

Navarro, B; (...); Iborra, M

Editorial Material. 10.1016/j.gastrohep.2018.05.008. 2019


Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.

Cañete F; (...); ENEIDA registry by GETECCU

Article. 10.1093/ibd/izz084. 2019


Adaptation of TECCU App Based on Patients ' Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups

Del Hoyo, J; (...); Aguas, M

Article. 10.3390/ijerph17061871. 2020

  • Open Access.

Adaptation of TECCU App based on patients' perceptions for telemonitoring inflammatory bowel disease: A qualitative study using focus groups

Francisco, JD; (...); Aguas, M

Meeting Abstract. 2020


Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Ballesta-López O; (...); Poveda-Andrés JL

Article. 10.1177/1078155220915953. 2020


Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU

Ballester Ferre, M. P.; (...); Minguez, M.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.727. 2021

  • Open Access.

Alopurinol-induced TEN and association with HLA B*58:01 in White patients

Saavedra, FP; (...); Romero, LCL

Letter. 10.1097/FPC.0000000000000358. 2018


Analysing criteria for price and reimbursement of orphan drugs in Spain.

Badia, X; (...); Tort, M

Article. 10.7399/fh.11147. 2019

  • Open Access.

Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


Antimicrobial stewardship programme implementation in a medical ward

Ruiz, J; (...); Poveda, JL

Article. 2018


Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study)

Bastida, G; (...); Barreiro-de Acosta, M

Meeting Abstract. 10.1093/ecco-jcc/jjy222.251. 2019

  • Open Access.

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis

Canete, F; (...); Domenech, E

Article. 10.14309/ctg.0000000000000218. 2020

  • Open Access.

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Chaparro, M; (...); EXIT Study Grp GETECCU

Article. 10.1177/1756284819874202. 2019

  • Open Access.

Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

Taxonera, Carlos; (...); Alba, Cristina

Article. 10.1111/apt.16964. 2022


Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis

Taxonera Samso, C.; (...); Alba, C.

Meeting Abstract. 2022


Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021

  • Open Access.

Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease

SÁEZ, E.; (...); BELTRÁN, B.

Article. 10.3390/nu11051062. 2019

  • Open Access.

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2018.12.027. 2019


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

  • Open Access.

Biomarkers response to anti-TNF treatment in Crohn's disease through the intestinal microbiota

Sanchis, L; (...); Cortes, X

Meeting Abstract. 2020


Certification of integral care IBD Units: Evaluation of a certification program (CUE)

Barreiro-de Acosta, M; (...); GETECCU

Meeting Abstract. 2020


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study.

Guerra I; (...); Gisbert JP

Article. 10.1093/ecco-jcc/jjz094. 2019


Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry

Gonzalez Munoza, C.; (...); Garcia-Planella, E.

Meeting Abstract. 2022


Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019

  • Open Access.

Colorectal cancer diagnosis in patients with inflammatory bowel disease in Spain: A room for improvement

Saldana, R; (...); Mateu, PN

Meeting Abstract. 2020


Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Megias-Vericat, JE; (...); Poveda, JL

Meeting Abstract. 2020


Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658].

Barreiro-de Acosta M; (...); Nos P

Correction. 10.1016/j.gastrohep.2021.02.001. 2021

  • Open Access.

Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.

Bermejo F; (...); Guerra I

Article. 10.1093/ibd/izab242. 2021

  • Open Access.

COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

  • Open Access.

Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020

  • Open Access.

COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018

  • Open Access.

Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.

Del Hoyo J, Aguas M

Letter. 10.1016/j.cgh.2020.06.016. 2021

  • Open Access.

COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021

  • Open Access.

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1111/hae.13733. 2019


Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

  • Open Access.

Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?

Del Hoyo, Javier; (...); Aguas, Mariam

Article. 10.1016/j.gastrohep.2021.08.006. 2021

  • Open Access.

Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?

Del Hoyo Francisco, J.; (...); Aguas, M.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.758. 2021

  • Open Access.

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.

Guasch M; (...); Domènech E

Article. 10.1111/jgh.15084. 2020

  • Open Access.

Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study

Cabre, E; (...); Domenech, E

Article. 10.1016/j.dld.2018.12.004. 2019


Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn's disease

Ladron Abia, P.; (...); Iborra, M.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.537. 2021

  • Open Access.

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.1080/17512433.2019.1573668. 2019


Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources

Sempere Robles, L.; (...); Ruiz, M. T.

Article. 2022


Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown

Sempere Robles, L.; (...); van-der Hofstadt, C.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.270. 2021

  • Open Access.

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019

  • Open Access.

DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019


DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019


Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019


Diagnostic yield of endoscopic ultrasound with fine-needle aspiration in pancreatic cystic lesions.

Argüello L; (...); Pons-Beltrán V

Article. 10.1016/j.gastrohep.2019.07.012. 2020


Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease

Iborra, M; (...); Beltran, B

Article. 10.1159/000493726. 2019


Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn's disease

Mateos, B; (...); Beltran, B

Meeting Abstract. 10.1093/ecco-jcc/jjy222.725. 2019

  • Open Access.

DNA methylation signatures associated with pathogenesis Crohn's disease-related genes

Tatay, IM; (...); Beltran, B

Meeting Abstract. 2019


Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis

Taxonera, C; (...); Alba, C

Article. 10.1080/03007995.2019.1579557. 2019


Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.

Rodríguez-Lago I; (...); Gisbert JP

Article. 10.1177/2050640620947579. 2020

  • Open Access.

Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply

Iborra, M, Beltran, B, Nos, P

Editorial Material. 10.1111/apt.15447. 2019

  • Open Access.

Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020

  • Open Access.

Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry

Mesonero, F; (...); Lopez-Sanroman, A

Article. 10.1111/apt.16315. 2021


Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.

Casanova MJ; (...); Gisbert JP

Article. 10.1093/ibd/izz192. 2020

  • Open Access.

Effectiveness and Safety of the Switch from Remicade (R) to CT-P13 in Patients with Inflammatory Bowel Disease

Chaparro, M; (...); Gisbert, JP

Article. 10.1093/ecco-jcc/jjz070. 2019

  • Open Access.

Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry

Chaparro, M; (...); Esteve M

Meeting Abstract. 10.1093/ecco-jcc/jjz203.563. 2020


Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.

Chaparro, Maria; (...); Lázaro Pérez-Calle, José

Article. 10.1093/ecco-jcc/jjab070. 2021

  • Open Access.

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn's disease. Data from clinical practice from the eneida registry

Ciria, MM; (...); Domenech, E

Meeting Abstract. 2020


Endoluminal radiofrequency ablation with SpyGlass in the management of cholangiocarcinoma.

Mansilla-Vivar R; (...); Pons-Beltrán V

Article. 10.17235/reed.2019.6230/2019. 2019

  • Open Access.

Endoscopic findings of paraduodenal or groove pancreatitis.

Lopez-Munoz, Pedro; (...); Pons-Beltran, Vicente

Article. 10.1055/a-1773-0499. 2022

  • Open Access.

Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study.

Barreiro-De Acosta, M; (...); Julia, B

Article. 10.1080/17474124.2019.1626717. 2019


EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.

Chaparro M; (...); Gisbert JP

Article. 10.1177/1756284819847034. 2019

  • Open Access.

Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU

Chaparro, M; (...); EpidemIBD Grp

Meeting Abstract. 10.1093/ecco-jcc/jjy222.914. 2019

  • Open Access.

Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU

Chaparro, M; (...); Gisbert, JP

Meeting Abstract. 2020


Epigenetics of Inflammatory Bowel Disease: Unraveling Pathogenic Events

Mateos, Beatriz; (...); Sandoval, Juan

Review. 10.1093/crocol/otz017. 2019

  • Open Access.

EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019


Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity.

Guijarro LG; (...); Hernández-Breijo B

Article. 10.3390/biomedicines10030727. 2022

  • Open Access.

Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment

Sanchis-Artero, L; (...); Cortes-Rizo, X

Article. 10.1038/s41598-021-88823-2. 2021

  • Open Access.

Evolution of the emotional impact in patients with early inflammatory bowel disease during and after Covid-19 lockdown.

Sempere L; (...); Hofstadt CV

Article. 10.1016/j.gastrohep.2021.03.004. 2021

  • Open Access.

Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018


EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019


Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.

Algaba A; (...); Bermejo F

Article. 10.1007/s10620-020-06424-x. 2020

  • Open Access.

Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019


Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia.

Huguet JM; (...); Paredes JM

Article. 10.3390/jcm11102786. 2022

  • Open Access.

Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.

Ladrón Abia P; (...); Bastida Paz G

Letter. 10.1016/j.gastrohep.2020.07.020. 2021


Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease

Chaparro, M; (...); Gisbert, JP

Meeting Abstract. 2019


Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease.

Chaparro M; (...); Gisbert JP

Article. 10.1177/1756284819867848. 2019

  • Open Access.

Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.

Aterido, A; (...); Julia, A

Article. 10.1038/s41397-019-0090-4. 2019


Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018

  • Open Access.

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

  • Open Access.

Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19.

Del Hoyo J; (...); Aguilera V

Editorial Material. 10.1111/jgh.15174. 2020

  • Open Access.

High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022

  • Open Access.

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021

  • Open Access.

Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease.

Moret-Tatay I; (...); Beltrán B

Article. 10.14309/ctg.0000000000000083. 2019

  • Open Access.

Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study

de Paredes, AGG; (...); Lopez-Sanroman, A

Article. 10.1016/j.pan.2020.02.007. 2020


Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.

Gutiérrez A; (...); Francés R

Article. 10.3389/fmed.2022.823900. 2022

  • Open Access.

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1080/10428194.2020.1839650. 2020


Impact of comorbidities on anti-TNF alpha response and relapse in patients with inflammatory bowel disease: the VERNE study

Marin-Jimenez, I; (...); Barreiro-de Acosta, M

Article. 10.1136/bmjgast-2019-000351. 2020

  • Open Access.

Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study

Marin-Jimenez, I; (...); Barreiro-de Acosta, M

Meeting Abstract. 10.1093/ecco-jcc/jjy222.433. 2019

  • Open Access.

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020

  • Open Access.

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019


Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020


Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?

Del Hoyo, J, Aguas, M

Editorial Material. 10.1016/j.gastrohep.2020.05.002. 2020

  • Open Access.

Incidence of opioid-induced esophageal dysfunction.

Abia, Pablo Ladron; (...); Garrigues, Vicente

Article. 10.1016/j.gastrohep.2022.05.004. 2022


Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

Chaparro, Maria; (...); Gisbert, Javier P.

Article. 10.3390/jcm10132885. 2021

  • Open Access.

Increased risk of thiopurine-related adverse events in elderly patients with IBD

Calafat, M; (...); ENEIDA Registry GETECCU

Article. 10.1111/apt.15458. 2019


Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience

Barreiro-de Acosta, M; (...); Nos, P

Article. 10.1002/ueg2.12105. 2021

  • Open Access.

Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)

Gonzalez Vivo, M.; (...); Marquez, L.

Meeting Abstract. 2022


Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019

  • Open Access.

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients

Lopez-Munoz, P; (...); Iborra, M

Article. 10.3390/nu11051059. 2019

  • Open Access.

Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019

  • Open Access.

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020


Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020

  • Open Access.

Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?

Pérez de Arce E; (...); Nos P

Article. 10.1016/j.gastrohep.2021.02.022. 2021


Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry

Calafat, M; (...); ENEIDA Registry GETECCU

Meeting Abstract. 10.1093/ecco-jcc/jjy222.548. 2019


Letter to the Editor on The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.

Gutierrez-Ontalvilla P; (...); Iborra M

Article. 10.1007/s00266-022-02960-1. 2022


Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study

Iborra, M; (...); Domenech, E

Article. 10.1093/gastro/goz029. 2019

  • Open Access.

Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey

Rodriguez-Lago, I; (...); Gisbert, JP

Article. 10.1016/j.gastrohep.2018.09.002. 2019


Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU

Chaparro, M.; (...); Gisbert, J. P.

Meeting Abstract. 2022


Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021

  • Open Access.

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022

  • Open Access.

Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021

  • Open Access.

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

  • Open Access.

Multiple duodenal diverticulosis as a rare cause of gastroduodenal bleeding.

Martínez Delgado S; (...); Alonso Lázaro N

Article. 10.1016/j.gastrohep.2020.07.029. 2022


National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021

  • Open Access.

Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.

Zabana Y; (...); Esteve M

Article. 10.3390/jcm11020421. 2022

  • Open Access.

New management of hepatolithiasis: Can surgery be avoided? (with video)

Mansilla-Vivar R; (...); Pons-Beltrán V

Article. 10.1016/j.gastrohep.2019.11.008. 2020


Non-guided self-learning program for high-proficiency optical diagnosis of diminutive and small colorectal lesions: A single-endoscopist pilot study

Bustamante-Balen, M; (...); Pons-Beltran, V

Article. 10.3748/wjg.v25.i10.1278. 2019

  • Open Access.

Oral ingestion versus endoscopic delivery of endoscopic capsule in patients with previous gastrointestinal surgery (ORENCES study): A Spanish multicentre observational study.

Giordano, Antonio; (...); SEED Group of Capsule Endoscopy and Enteroscopy

Article. 10.1016/j.gastrohep.2020.11.005. 2021


Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics

Alemany-Cosme, E; (...); Beltran, B

Review. 10.3390/antiox10010064. 2021

  • Open Access.

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020

  • Open Access.

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

  • Open Access.

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.

Riestra S; (...); Domènech E

Article. 10.3390/jcm11133915. 2022

  • Open Access.

Periendoscopic management of antiplatelet therapy: Prospective evaluation of adherence to guidelines

Plume, G; (...); Bustamante-Balen, M

Article. 10.1016/j.gastrohep.2019.03.010. 2019


Peroral cholangiopancreatoscopy as a rescue method for a trapped pancreatic guidewire

Mansilla-Vivar, R; (...); Beltran, VP

Editorial Material. 10.1055/a-0820-1160. 2019

  • Open Access.

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020

  • Open Access.

Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021

  • Open Access.

Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020


Plasma Oncostatin M, TNF-a, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.

Mateos B; (...); Beltrán B

Article. 10.1159/000508069. 2020


PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019

  • Open Access.

Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021

  • Open Access.

Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021

  • Open Access.

Prevalence, features and outcomes of splachnic vein thrombosis in inflammatory bowel disease. A nationwide, retrospective study from the ENEIDA registry

Masnou, H; (...); Eneida-GETECCU Registry

Meeting Abstract. 2020


Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021

  • Open Access.

Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery

Baldan-Martin, M.; (...); Gisbert, J. P.

Meeting Abstract. 2022


Psychological burden in newly diagnosed IBD patients: Differences between Crohn's Disease and Ulcerative Colitis in early IBD

Bernabeu, P.; (...); Sempere, L.

Article. 2022


Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain

Hernandez Camba, A.; (...); Barreiro, M.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.312. 2021

  • Open Access.

Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.

Hernandez Camba, Alejandro; (...); Barreiro-de Acosta, Manuel

Article. 10.1016/j.gastrohep.2021.08.007. 2021

  • Open Access.

Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

Taxonera, C; (...); Nos, P

Article. 10.1016/j.dld.2019.01.002. 2019


Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.

Iborra M; (...); Nos P

Article. 10.1038/s41598-020-73577-0. 2020

  • Open Access.

Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients

Iborra, M; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.683. 2019

  • Open Access.

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease.

Huguet, JM; (...); Paredes, JM

Article. 10.12998/wjcc.v9.i36.11285. 2021

  • Open Access.

Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry

Iborra, M; (...); Nos, P

Article. 10.1111/apt.15958. 2020


Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry

Iborra Colomino, M. I.; (...); Nos, P.

Meeting Abstract. 2020


Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry

Iborra, M; (...); Chaparro, M

Article. 10.1111/apt.15371. 2019


Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry

Iborra, M; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.629. 2019

  • Open Access.

Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.

Hernandez-Camba, A.; (...); GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)

Article. 10.1016/j.dld.2021.10.002. 2021


Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015

Gonzalez, J; (...); Cohort Spanish HIV Res Network Co

Article. 10.1016/j.eimc.2019.02.007. 2019


Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis

Gonzalez-Lama, Y; (...); Gomollon, F

Article. 10.1016/j.gastrohep.2020.01.005. 2020

  • Open Access.

Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease.

Boscá MM; (...); Hinojosa J

Review. 10.1016/j.gastrohep.2019.09.012. 2020

  • Open Access.

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis.

Barreiro-de Acosta M; (...); Nos P

Editorial Material. 10.1016/j.gastrohep.2019.08.001. 2019

  • Open Access.

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.

Barreiro-de Acosta M; (...); Nos P

Article. 10.1016/j.gastrohep.2020.04.004. 2020

  • Open Access.

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease

Guardiola, J; (...); Representacion GETECCU

Review. 10.1016/j.gastrohep.2018.05.029. 2018

  • Open Access.

Recommendations of the Valencian Society of Digestive Pathology for the use of telemedicine and non-contact consultations.

Jover, Rodrigo; (...); Nos, Pilar

Article. 10.1016/j.gastrohep.2021.04.009. 2022

  • Open Access.

Regression of a giant pseudopolyp in a patient with colonic Crohn's disease after therapy with infliximab.

Sánchez Melgarejo JF; (...); Nos P

Article. 10.17235/reed.2019.6252/2019. 2019

  • Open Access.

Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.

Bermejo F; (...); Guerra I

Article. 10.1093/ibd/izab015. 2021


Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved.

Guijarro, Luis G.; (...); On Behalf Of The Predicrohn Study Group From Geteccu

Article. 10.1016/j.biopha.2021.112239. 2021

  • Open Access.

Relevance of Clinical Cases.

Balaguer, Francesc; (...); Saez Gonzalez, Esteban

Editorial Material. 10.1016/j.gastrohep.2022.02.001. 2022


Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease.

Pous S; (...); Nos P

Article. 10.1016/j.gastrohep.2019.11.010. 2020


Reviewing the therapeutic role of budesonide in Crohn's disease

Lopez-Sanroman, A; (...); Domenech, E

Review. 10.1016/j.gastrohep.2018.05.013. 2018

  • Open Access.

Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.

Calafat M; (...); ENEIDA Study Group of GETECCU

Article. 10.1093/ecco-jcc/jjab213. 2021


Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry

Calafat, M; (...); Domenech, E

Meeting Abstract. 10.1093/ecco-jcc/jjy222.561. 2019


Risk of postoperative morbidity in patients having bowel resection for colonic Crohn's disease

Iesalnieks I; (...); El-Hussuna A

Article. 10.1007/s10151-018-1904-0. 2018


Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU

Chaparro, M.; (...); Gisbert, J. P.

Meeting Abstract. 2022


Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-TNF-alpha Treatment for Crohn's Disease

Saez-Gonzalez, E; (...); Beltran, B

Letter. 10.1038/s41395-018-0420-1. 2019


Secukinumab-induced ulcerative colitis: opening Pandora's box of immunity

Fernandez-de La Varg, M; (...); Paz, GB

Letter. 10.1016/j.gastrohep.2019.12.004. 2020


SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020

  • Open Access.

Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease

Taxonera, C; (...); CONVERT Study Grp GETECCU

Article. 10.1093/ecco-jcc/jjy104. 2018


Should professionals provide their patients with digital health training resources?

Piudo, AE; (...); Marcos, NM

Meeting Abstract. 2020


Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.

Mínguez Sabater A; (...); Bastida G

Article. 10.1016/j.gastrohep.2020.09.003. 2022


SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

  • Open Access.

Specific plasma micro-RNA profiles for prediction of recurrence in Crohn's disease in pre-surgery and established recurrence scenarios

Moret, I; (...); Beltran, B

Meeting Abstract. 2020


Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications.

Moret-Tatay, Ines; (...); Beltran, Belen

Article. 10.14309/ctg.0000000000000416. 2021

  • Open Access.

Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.

Bastida G; (...); Nos P

Article. 10.3390/nu13061770. 2021

  • Open Access.

Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)

Chaparro, M.; (...); ECCO CONFER Taskforce

Meeting Abstract. 2022


Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]

Chaparro, Maria; (...); Julsgaard, Mette

Article. 10.1093/ecco-jcc/jjac050. 2022

  • Open Access.

Survey of adherence to treatment in inflammatory bowel disease. ENADEII study.

Alonso-Abreu I; (...); Quintero-Carrión E

Article. 10.1016/j.gastrohep.2019.10.007. 2020


Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY

Abreu, IA; (...); GETECCU

Meeting Abstract. 2019


Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry.

Calafat M; (...); Domènech E

Article. 10.1093/ecco-jcc/jjaa055. 2020


Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022

  • Open Access.

Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.

Del Hoyo J; (...); Aguas M

Article. 10.2196/15505. 2019

  • Open Access.

Terapia de rescate con ciclosporina oral tras el uso de ustekinumab en colitis ulcerosa resistente a múltiples tratamientos.

Abia PL; (...); Niclós BB

Letter. 10.1016/j.gastrohep.2021.04.012. 2021


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

  • Open Access.

The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.

Ladron Abia, Pablo; (...); Iborra, Marisa

Article. 10.1016/j.gastrohep.2022.01.004. 2022


The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.

Gutierrez-Ontalvilla, P.; (...); Iborra, M.

Article. 10.1007/s00266-021-02718-1. 2022


The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions.

Zabana Y; (...); Domènech E

Article. 10.1016/j.gastrohep.2020.05.007. 2020

  • Open Access.

The Female Sexual Function Index to assess patients with moderate to severe vulvar lichen sclerosus.

Gutierrez-Ontalvilla P; (...); Vicente D

Letter. 10.1684/ejd.2019.3580. 2019


The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study.

Echarri A; (...); Muñiz J

Article. 10.1089/tmj.2018.0264. 2020

  • Open Access.

Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

Ferreiro Iglesias, R.; (...); Barreiro-de Acosta, M.

Meeting Abstract. 2022

  • Open Access.

Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.

Chaparro M; (...); Gisbert JP

Article. 10.1093/ecco-jcc/jjaa145. 2021


Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020


Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020

  • Open Access.

TREATMENT OF IRON DEFICIENCY WITHOUT ANEMIA WITH FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PROSPECTIVE EVALUATION OF CLINICAL AND PATIENT-REPORTED OUTCOMES IN SPAIN

Huguet, J. M.; (...); Munoz, M.

Meeting Abstract. 2022


Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFalpha used for the treatment of IBD: Results from the VERNE study.

Bastida G; (...); Barreiro-de Acosta M

Article. 10.1016/j.dld.2021.06.005. 2021

  • Open Access.

Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?

Bejar, S; (...); Mateu, PN

Meeting Abstract. 2020


Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA

Borras, N; (...); Corrales, I

Article. 10.3324/haematol.2018.203166. 2019

  • Open Access.

Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy

Garcia, SV; (...); Andres, JLP

Article. 10.1016/j.yrtph.2018.10.002. 2018


USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Dominguez Hernandez, L.; (...); Gomez Segui, I

Meeting Abstract. 2019

  • Open Access.

Use of Magnetic Resonance Index of Activity (MaRIA) in the preoperative assessment of small bowel Crohn's disease.

Pous-Serrano, S; (...); Garcia-Granero, E

Article. 10.1016/j.ciresp.2019.06.018. 2019


Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry

Camba, AH; (...); Ramos, L

Meeting Abstract. 2020


Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

Chaparro, M; (...); Gisbert, JP

Article. 10.1097/MEG.0000000000001706. 2020


Ustekinumab as an opportunity for refractory Ulcerative Colitis patients

Iborra, M.; (...); Nos, P.

Meeting Abstract. 2022


Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients

Mateos, B.; (...); Beltran, B.

Meeting Abstract. 10.1093/ecco-jcc/jjab076.697. 2021

  • Open Access.

Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents

Iborra, M; (...); Nos, P

Article. 10.1016/j.gastrohep.2018.06.001. 2018


Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse

Iborra, M; (...); Nos, P

Article. 10.1007/s10620-018-5429-1. 2019


Campos d'Estudi

Compartir el projecte